Bacterial Vaginosis Linked to Cervical Intraepithelial Neoplasia

Publication
Article
OncologyONCOLOGY Vol 9 No 4
Volume 9
Issue 4

Bacterial vaginosis, the most widespread vaginal infection in the United States, is associated with a 357% increase in the incidence of cervical intraepithelial neoplasia (CIN), an abnormality of cervical

Bacterial vaginosis, the most widespread vaginal infection in the United States, is associated with a 357% increase in the incidence of cervical intraepithelial neoplasia (CIN), an abnormality of cervical cells that may lead to cervical cancer, according to a study published in the Scandinavian journal Acta Obstetricia et Gynecologica Scandinavica.

Cervical cancer is believed to be the most common form of cancer in women worldwide. While screening with Pap smears has dramatically reduced the incidence of this cancer in the United States, an estimated 2.5 million American women are diagnosed with low-grade cervical cytologic abnormalities each year.

According to a retrospective evaluation of Pap smears obtained in 6,150 women, reported by Dr. Jens Platz-Christensen and colleagues at Sahlgrenska University Hospital in Goteborg, Sweden, bacterial vaginosis was diagnosed, by detection of clue cells in Pap smears, in 617 (10%) of the patients. Cervical intraepithelial neoplasia was found in 5% of these women with vaginosis, as compared with 1.4% of the women without vaginosis. Moreover, when early-stage CIN was excluded, second- and third-stage CIN occurred in 2.9% of the patients with bacterial vaginosis but in only .4% of those without this infection.

"The possibility exists that bacterial vaginosis is in some way associated with the development of cervical intraepithelial neoplasia," the authors conclude, noting that bacterial vaginosis may be a cofactor to the potentially cancer-causing human papillomavirus (HPV). The association between HPV and the development of CIN and cervical cancer is well documented. The abnormal vaginal flora in bacterial vaginosis can produce nitrosamines. These carcinogens may act synergistically with HPV to damage epithelial cells, thus aiding in the development of CIN.

A growing body of scientific evidence has also linked bacterial vaginosis with an increased risk of pelvic inflammatory disease, as well as cervicitis, endometritis, recurrent urinary tract infections, postoperative infection, and other health complications. Because of this mounting evidence, an increasing number of physicians advocate screening for bacterial vaginosis as part of the routine gynecologic examination. They note that, while a traditional Pap smear alone is unreliable for detection of this condition, simple office test procedures for bacterial vaginosis and other vaginal infections can be conducted in less than 3 minutes.

Clinical signs of bacterial vaginosis include a foul or fishy odor of varying degrees; a thin, milk-like discharge; a vaginal pH exceeding 4.5; and the presence of clue cells (epithelial cells coated with bacteria) in vaginal cultures.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content